The biological importance of tumour-associated stroma is becoming increasingly apparent, but its clinical utility remains ill-defined. For stage II/Dukes B colorectal cancer (CRC), clinical biomarkers are urgently required to direct therapeutic options. We report here prognostic/predictive analyses, and molecular associations, of stromal morphometric quantification in the Quick and Simple and Reliable (QUASAR) trial of CRC. Methods and results: Relative proportions of tumour epithelium (PoT) or stroma (PoS) were morphometrically quantified on digitised haematoxylin and eosin (H&E) sections derived from 1800 patients enrolled in QUASAR, which randomised 3239 (91% stage II) CRC patients between adjuvant fluorouracil/folinic acid (FUFA) chemotherapy and observation. The prognostic and predictive values of PoT/PoS measurements were determined by the use of stratified logrank analyses. A high proportion of tumour stroma (≥50%) was associated with an increased recurrence risk: 31.3% (143/457) recurrence for ≥50% versus 21.9% (294/1343) for <50% [rate ratio (RR) 1.62; 95% confidence interval (CI) 1.30-2.02; P < 0.0001]. Of patients with stromal proportions of ≥65%, 40% (46/115) had recurrent disease within 10 years. The adverse prognostic effect of a high stromal proportion was independent of established prognostic variables, and was maintained in stage II/ Dukes B patients (RR 1.62; 95% CI 1.26-2.08; P = 0.0002). KRAS mutation in the presence of a high stromal proportion augmented recurrence risk (RR 2.93; 95% CI 1.87-4.59; P = 0.0005). Stromal morphometry did not predict response to FUFA chemotherapy. Conclusions: Simple digital morphometry applied to a single representative H&E section identifies CRC patients with a >50% higher risk of disease recurrence. This technique can reliably partition patients into subpopulations with different risks of tumour recurrence in a simple and cost-effective manner. Further prospective validation is warranted.
Aims:
The biological importance of tumour-associated stroma is becoming increasingly apparent, but its clinical utility remains ill-defined. For stage II/Dukes B colorectal cancer (CRC), clinical biomarkers are urgently required to direct therapeutic options. We report here prognostic/predictive analyses, and molecular associations, of stromal morphometric quantification in the Quick and Simple and Reliable (QUASAR) trial of CRC. Methods and results: Relative proportions of tumour epithelium (PoT) or stroma (PoS) were morphometrically quantified on digitised haematoxylin and eosin (H&E) sections derived from 1800 patients enrolled in QUASAR, which randomised 3239 (91% stage II) CRC patients between adjuvant fluorouracil/folinic acid (FUFA) chemotherapy and observation. The prognostic and predictive values of PoT/PoS measurements were determined by the use of stratified logrank analyses. A high proportion of tumour stroma (≥50%) was associated with an increased recurrence risk: 31.3% (143/457) recurrence for ≥50% versus 21 .9% (294/1343) for <50% [rate ratio (RR) 1.62; 95% confidence interval (CI) 1.30-2.02; P < 0.0001]. Of patients with stromal proportions of ≥65%, 40% (46/115) had recurrent disease within 10 years. The adverse prognostic effect of a high stromal proportion was independent of established prognostic variables, and was maintained in stage II/ Dukes B patients (RR 1.62; 95% CI 1.26-2.08; P = 0.0002). KRAS mutation in the presence of a high stromal proportion augmented recurrence risk (RR 2.93; 95% CI 1.87-4.59; P = 0.0005). Stromal morphometry did not predict response to FUFA chemotherapy. Conclusions: Simple digital morphometry applied to a single representative H&E section identifies CRC patients with a >50% higher risk of disease recurrence. This technique can reliably partition patients into subpopulations with different risks of tumour recurrence in a simple and cost-effective manner. Further prospective validation is warranted.
Introduction
The use of adjuvant chemotherapy in colorectal cancer (CRC) following presumptive curative resection is directed by high-quality pathological assessment. [1] [2] [3] Detection of tumour within lymph nodes (stage III disease) is generally regarded as an absolute indication for adjuvant therapy, 1, 4, 5 because of significant clinical benefit [~10% absolute improvement in overall survival (OS)]. 6, 7 The value of adjuvant chemotherapy in locally advanced, node-negative (stage II) disease is less clear, because the more modest benefits (~4% improvement in OS) 8 may not outweigh the toxicity and patient inconvenience. 1, 9, 10 Thus, adjuvant chemotherapy is generally restricted to a minority of stage II patients with 'high-risk' pathological features including extramural vascular and/or peritoneal invasion. 1, 11, 12 Such features impart a recurrence risk of similar magnitude to that associated with lymph node metastasis, 2 and so serve to identify stage II patients who may derive worthwhile benefit from adjuvant regimens. 1, 4, 5 A limitation of this approach is that identification of such features is subjective, with variability in reporting quality and reproducibility. 3, 13 Also, only a minority of recurrences among these 'high-risk' patients will be prevented by 'appropriate' chemotherapy, 8, 10, 14 and it is not currently possible to identify who is more or less likely to benefit. 15 Consequently, the identification and clinical validation of effective prognostic and, in particular, predictive biological indicators would help facilitate therapeutic decisions.
Mismatch repair (MMR)/microsatellite instability (MSI) testing can identify CRC patients at a reduced risk of recurrence for whom adjuvant therapy is usually not indicated. 14, [16] [17] [18] However, only a minority of CRC patients, 12-15% at most, show MSI and/or attenuated expression of one or more MMR proteins. 16, 17 The Oncotype DX recurrence score has been prospectively validated for assessment of recurrence risk in postoperative stage II colon cancer patients, but is of only modest prognostic value and is not predictive of chemotherapy benefit. 19 Widely applicable biomarkers are thus required, particularly ones that negate the need for expensive molecular testing, [20] [21] [22] [23] for cost-effective application in a diverse, non-specialist setting.
Associations between disease recurrence and cancer-associated stromal gene [23] [24] [25] [26] [27] or protein [28] [29] [30] [31] [32] [33] [34] [35] expression have been reported in a variety of malignant conditions, with some evidence of differential chemotherapeutic response being defined by stromal gene expression profiles. [36] [37] [38] In CRC, the potential prognostic value of stromal gene expression analysis is highlighted by inclusion in the Oncotype DX colon recurrence score. 23 Although the majority of studies have been performed at the transcriptomic or proteomic level, several studies have indicated that, with the use of established mathematical principles, [39] [40] [41] [42] simple, inexpensive, visual evaluation of tumour composition [43] [44] [45] [46] [47] or stromal phenotype 48, 49 may yield equally valuable prognostic information.
Studies by Mesker et al., 50, 51 West et al. 52 and Huijbers et al. 47 have suggested that simple visual 47, 50, 51 or morphometric 52 assessment of CRCs provides independent prognostic information, a premise recently tested in the VICTOR CRC trial. 47 To improve on the reproducibility of these visual estimation methods described by Huijbers et al., 47 we have developed a quantitative compositional analysis technique utilising digital pathology. 53 This methodology, however, has so far only been tested in a small cohort of 145 all-stage CRC patients. 52 Given the biological plausibility, the existing literature, and the recent recognition of CRCs with mesenchymal/stroma-rich gene signatures as being biologically distinct and clinically significant tumour subpopulations, 54 we hypothesise that quantitative tumour-stromal compositional analysis might represent a simple but powerful methodology to determine the risk of disease recurrence and differential response to adjuvant chemotherapy in CRC. We report here the results of a test of this hypothesis utilising digitised material and clinicopathological data from the Quick and Simple and Reliable (QUASAR) trial, which randomised 3239 predominantly stage II (91%) CRC patients between 6 months of fluorouracil/folinic acid (FUFA) chemotherapy and observation. 8 
Materials and methods

E T H I C S
Ethical approval was obtained from both the West Midlands Multi-Centre Research Ethics Committee (JR/MT/MREC/02/7/56a) and the Northern and Yorkshire Research Ethics Committee (08/H0903/ 62).
P A T I E N T S
The design and details of QUASAR (ISRCTN82375386) are reported elsewhere. 8 Briefly, 3239 patients (after curative resection for colon or rectal cancer; 91% stage II disease) were randomized to FUFA chemotherapy (n = 1622) or observation only (n = 1617), with chemotherapy being considered in the event of recurrence.
S T U D Y D E S I G N
Datasets were randomly partitioned into exploratory and validatory groups (Figure 1 ). For initial analyses, an exploratory dataset (n = 399), representative of the entire study cohort, was used to develop a priori prognostic [50] [51] [52] and predictive hypotheses by the use of data derived from three specific analytical tumour regions ( Figure 2 ). Independent validation was performed with a separate validatory patient cohort dataset (n = 1800). All pathological and laboratory assessments were undertaken blind to the patients' treatment allocation and clinical outcomes.
Pathological data (TNM 5) were abstracted by central review of anonymised histopathological reports collected from local units.
One tumour block per patient was selected for analyses. When more than one block was available, blocks were chosen to optimally represent the area of maximal tumour infiltration of the bowel wall. Histological sections (thickness, 5 lm) were cut from selected tumour blocks and stained with haematoxylin and eosin (H&E) according to standard methodologies. H&E sections were digitised at 920 magnification (0.46 lm per pixel) with an automated scanning system (Aperio XT; Aperio Technologies, Vista, CA, USA). Slide viewing for quality control (QC) and all subsequent quantification processes were performed with open source slide-viewing software (APERIO IM-AGESCOPE v10.2.2.2352; Aperio Technologies). Following image QC, and methodological and statistical validation with existing datasets, a systematic random sample of 50 points was superimposed on selected areas (Figure 2 ) with web-based virtual graticule software (RANDOMSPOT; University of Leeds, Leeds, UK).
For exploratory analyses (Figure 1 ), three areas from each selected H&E section were identified for random point grid application ( Figure 2 ). The luminal tumour area was defined as a 9-mm 2 area of greatest tumour epithelial cell density at the luminal surface of the tumour (Figure 2A ). The highest tumour density area was defined as a 9-mm 2 area of highest tumour cell density (if not located at the luminal surface) ( Figure 2B ). The whole tumour (WT) area included the total area of tumour infiltration extending from the luminal surface and encompassing the lateral and deep invasive fronts of tumour (Figure 2C ). For 9-mm 2 regions, large areas of necrosis and mucin were avoided if possible. Tumour morphometry was determined by counting the frequency of occurrence of specific phenotypic categories underlying each of the 50 points. The following categories were used; 1, tumour epithelium; 2, tumour-associated stroma; 3, necrosis; 4, vessel; 5, inflammation; 6, tumour lumen; 7, mucin; 8, muscle; and 0, non-informative/unclassifiable. Tumour morphometry was performed by technical staff under the direct supervision of experienced pathologists (G.H. and P.Q.).
For final outcome analyses, relative tumour composition was expressed as a percentage of total informative points for tumour epithelium [proportion of tumour (PoT): phenotype category 1 only] or stroma [proportion of stroma (PoS): phenotype category 2 only] or other categories (phenotype categories 3-8).
D E T E R M I N A T I O N O F M O R P H O M E T R I C S T R A T I F I C A T I O N C U T -O F F P O I N T S
For prognostic/predictive analyses, we applied the 'pool adjacent violators' algorithm to the continuous variables PoT or PoS to determine points where the relationship between the measured variable (e.g. stroma) and the recurrence risk showed a distinct change. [55] [56] [57] [58] [59] Analyses were performed (by K.H. and R.G.) across all tumour/stromal measurements derived from each area within the training set (n = 399) indicating the most appropriate cut-off values to stratify scores into two (<50% and ≥50%) or four groups (<35%, 35-49%, 50-64%, and ≥65%).
S T A T I S T I C S A N D B I O I N F O R M A T I C S
The prognostic/predictive value of PoT/PoS measurements were determined with stratified log-rank analyses. 60 For analyses of the prognostic value of PoT or PoS, recurrence was used as the outcome measure. Recurrence is a reliable marker of the natural history of the cancer, and correlates well with the effects of adjuvant chemotherapy on survival. 61 Recurrence was calculated as the time elapsed from randomisation to recurrence, with censoring at last contact with patient or death without recurrence. For assessment of the prognostic value of variables, recurrence rates over the whole follow-up period were analysed. Because adjuvant FUFA reduces the risk of recurrence only in the first 2 years following randomisation, with no further benefit, or loss of benefit, thereafter, The integrity of scoring data was validated by interobserver comparison analysis of scores generated by two independent observers using kappa statistics on 2975 individual data points. Interobserver variability analyses were discontinued after 10 cases, because of extremely high interobserver agreement (see below). Subsequent to interobserver analyses, all generated data were visually screened by experienced pathologists (G.H. and P.Q.).
Results
Tumour tissue was obtained for 75% (2439/3239) of QUASAR participants, with material from 2199 patients being suitable for analysis (Figure 1 ). Comparisons of morphometry scores generated by two independent observers on 2975 informative data points confirmed a high agreement rate of 99.1% [Cohen's kappa = 0.986 (95% CI 0.985-0.990; P < 0.001)].
E X P L O R A T O R Y D A T A S E T A N A L Y S E S
Analyses of the 399-patient exploratory dataset provided no indication of any significant association between tumour or stromal density and chemotherapeutic efficacy ( Figure S1 ); prognostic analyses of the exploratory dataset therefore included both treated and control patients. A higher percentage of stromal cells was associated with worse prognosis in the exploratory dataset, particularly in the 'highest' and 'whole' stroma categorisations ( Figures S2-S7) . A lower percentage of tumour cells was also associated with worse prognosis in the exploratory dataset, particularly in the 'highest' and 'luminal' tumour categorisation.
V A L I D A T O R Y D A T A S E T A N A L Y S E S
Analyses of the 1800-patient validatory dataset also provided little evidence for any association between tumour or stroma density and chemotherapy efficacy (see below). Therefore, prognostic analyses of the validatory data again included both chemotherapy-treated and control patients.
There was a highly significant trend of increasing 10-year recurrence risk with increasing stromal proportions in the WT area in the test dataset (log-rank P < 0.0001; Figure 3 ). In contrast, other stromal and tumour scores were only weakly associated with worse prognosis (Figures S8-S12 ). This highly significant association in the whole stroma categorization is consistent with the exploratory data analyses, in which the association was strongest in the whole and highest stroma categories, whereas the lack of association in the highest stroma category is not.
For stromal proportions of ≥65% in the WT area, the 10-year risk of recurrence was 43%, as compared with 25% for tumours with scores of <50%. The adverse prognostic impact of higher WT PoS scores remained highly significant (P = 0.0002) in analyses restricted to stage II/Dukes B patients only (Figure 4) . Notably, there was no association between the pattern of recurrence (local versus distant) and increasing stromal proportions within the WT area (P = 0.105).
The distribution of PoS risk categories derived from the WT area differed significantly by tumour site, stage, histological subtype, and MMR phenotype (Table 1 ). There were significantly more tumours classified as PoS ≥65% in the rectum than in the colon: 11.4% (43/377) versus 5.1% (72/1423) (P < 0.0001). There were more low (<35%) PoS scores in Dukes B than in Dukes C lesions: 41.1% (658/1603) versus 26.7% (43/161) (P = 0.002). Predictably, there was a lower frequency of PoS ≥65% lesions in mucinous tumours than in adenocarcinomas: 1.9% (3/162) versus 6.4% (95/1473) (P < 0.0001). The weak (P = 0.012) association of lower scores in the deficient MMR phenotype is also unsurprising, given the previously reported interactions between deficient MMR, anatomical location, and mucinous and medullary histology.
To investigate whether confounding with other pathological prognostic variables might at least partly explain the association of high stromal counts with recurrence, we undertook analyses stratified by these other variables by using a binary dichotomisation (<50% low; ≥50% high) of PoS scores. The risk of recurrence was >50% higher in the 25% (457/1800) of patients with high (≥50%) PoS scores than in patients with low (<50%) PoS scores [rate ratio (RR) 1.61; 95% confidence interval (CI) 1.30-2.00; P < 0.0001)] ( Figure 5 ). Analyses stratified by chemotherapy allocation, tumour site and stage did not indicate any significant variability in the prognostic importance of stroma, and nor did any other of the variables tested, except for the analyses stratified by KRAS mutation status, in which significant (P = 0.001) heterogeneity was seen, with a stronger prognostic association being seen in KRAS mutant tumours (RR 2.93; 95% CI 1.85-2.55) than in KRAS wild-type tumours (RR 1.14; 95% CI 0.60-1.62) (Figure 5) .
We investigated any differential chemotherapeutic response by PoS measurements, with 2-year disease recurrence as the outcome (Figure 6 ). There were one-third fewer recurrences with chemotherapy than in controls within the 2-year post-randomization period (unstratified analyses: RR 0.64; 95% CI 0.49-0.84; P = 0.001). Analyses substratified by increasing WT PoS scores failed to demonstrate a significant interaction between chemotherapy benefit and PoS scores (P trend = 0.22; Figure 6 ).
Unexpectedly, the beneficial effect of chemotherapy was as strong in analyses of all recurrences as in analyses of 2-year recurrence (Figures S13-S16): 20.8% (183/880) of adjuvant-treated patients had recurrences at 10 years as compared with 27.6% (254/920) of untreated patients (RR 0.71; 95% CI 0.59-0.85; P = 0.0003). There was a suggestion (P trend = 0.039) that the reduction in 10-year recurrence with chemotherapy increased with increasing PoS score in the WT area ( Figures S13-S16) .
Analyses of other prognostic variables were performed to compare the prognostic strength of these variables with that of stromal count, and to determine whether their prognostic value was independent of stromal count ( Figures S17-S23) A borderline significant interaction between stroma and Dukes stage (P trend = 0.032) was seen, with no apparent prognostic effect of nodal status in tumours with ≥65% PoS scores. No interactions between TNM T category (TNM 5) and increasing PoS scores were identified, with the favourable prognostic effect of T3 versus T4 disease appearing to be similar across PoS subgroups ( Figure S18 ). Small subgroup numbers (two recurrences in five patients with deficient MMR tumours with ≥65% PoS scores) precluded any meaningful investigation of potential interactions ( Figure S20 1.39; 95% CI 1.09-1.78; P = 0.009)] ( Figure S21 ), with the adverse prognostic effect of tumour PoS appearing to be greater in KRAS mutant than in KRAS wild-type tumours ( Figure S21 ). These observations parallel the analysis of dichotomised stroma stratified by KRAS mutation status ( Figure 5 ). BRAF status was non-prognostic ( Figure S22 ).
Discussion
By applying simple digital morphometry to tumour blocks from 2199 QUASAR CRC trial patients, 8 we have demonstrated the powerful prognostic value of tumour-stromal counts; our division of tumours into four prognostic groups based on cut-offs in the Test for heterogeneity between subgroups: χ = 2·6; P = 0·10 Test for heterogeneity between subgroups: χ = 6·2; P = 0·10 Test for heterogeneity between subgroups: χ = 0·0; P = 0·93
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Test for heterogeneity between subgroups: χ = 2·6; P = 0·27 Test for heterogeneity between subgroups: χ = 0·0; P = 0·91 Test for heterogeneity between subgroups: χ = 0·2; P = 0·88 Test for heterogeneity between subgroups: χ = 0·7; P = 0·39 Test for heterogeneity between subgroups: χ = 3·3; P = 0·068 Test for heterogeneity between subgroups: χ = 1·9; P = 0·17 Test for heterogeneity between subgroups: χ = 10·6; P = 0·001
Test for heterogeneity between subgroups: χ = 0·6; P = 0·42 Test for heterogeneity between subgroups: χ = 2·0; P = 0·58 Test for heterogeneity between subgroups: χ = 1·3; P = 0·73
Test for trend between subgroups: χ = 0·9; P = 0·35 Test for trend between subgroups: χ = 1·2; P = 0·28
Test for heterogeneity between subgroups: χ = 2·8; P = 0·42 Test for trend between subgroups: χ = 0·2; P = 0·63 Test for heterogeneity between subgroups: χ = 4·7; P = 0·20 Test for trend between subgroups: χ = 0·1; P = 0·77 Test for heterogeneity between subgroups: χ = 4·5; P = 0·22 Test for trend between subgroups: χ = 0·0; P = 0·86 Test for heterogeneity between subgroups: χ = 2·0; P = 0·56 Test for trend between subgroups: χ = 1·5; P = 0·22 validatory cohort was confirmed in the test data, with high intratumoral stromal proportion (>65%) being associated with a disease recurrence risk approximately twice that of patients whose tumours contained low intratumoral stromal proportions (<50%).
Our primary analysis with 2-year disease recurrence as outcome failed to substantiate any predictive chemotherapeutic effect of stromal count ( Figure 6 ). However, the benefits of chemotherapy appeared to increase with increasing stromal count, and this trend reached statistical significance in analyses of all recurrence stratified by intratumoral stromal proportion, suggesting that the benefits of chemotherapy are at least as good in the higher-risk stroma groups. This contrasts with previous reports suggesting that tumour-associated stroma may attenuate the efficacy of chemotherapeutic agents. [62] [63] [64] [65] [66] [67] [68] [69] [70] Although some propose pharmacological targeting of tumour-associated stroma as a mechanism to counter chemoresistance (and thus enhance chemotherapeutic efficacy) in cancer, [70] [71] [72] [73] the present study provides no support for this approach, at least in CRC.
The mechanism by which varying proportions of intratumoral stroma influence clinical outcome (also reported in breast, 43, 46 lung, 44, 74 ovarian, 75 cutaneous 45 and prostatic 76 neoplasia) is unknown. Postulated theories commonly relate to stroma-associated cellular phenotypes, and include enhanced proinvasive signalling by intrastromal myofibroblasts 77 or growth factor/cytokine production by cancer-associated fibroblasts inducing angiogenesis, and increased tumour growth and invasion. 71, [78] [79] [80] [81] Other possible explanations may involve mechanisms related to tumour hypoxia 82 and/or tumour-associated inflammation. 71, 83 The possibility that different proportions of tumour and stroma may simply indirectly reflect the stage of disease has been previously suggested. 51, 52 We found no evidence for this potential explanation for the prognostic effect of stroma, with similar findings being made in stratified and unstratified analyses, and no interaction being found between stromal proportions, Dukes categories and TNM T categories.
Stromal transforming growth factor (TGF)-b, 84 ,85 a critical regulator of epithelial-mesenchymal transition, 86 is required to support metastatic dissemination when mutational inactivation of TGF-b has occurred, as is common in CRC. 87 In view of the possible role of stroma-derived TGF-b in the promotion of metastases in CRC, 87 the observation that tumours with KRAS mutation and high stromal proportions had a significantly higher recurrence risk than tumours with wild-type KRAS and high stromal proportions is noteworthy. There is abundant evidence indicating that RAS signalling operates in unison with TGF-b to enhance tumour cell invasiveness, either directly 88, 89 or by suppressing TGF-b-mediated growth-inhibitory signals. 90, 91 A note of caution, however, is that the association between stroma and KRAS mutation was unexpected, so our findings need to be confirmed, but should encourage further investigation.
In summary, our analyses of the largest reported validation dataset confirm the prognostic value of simple morphometric analyses, and reciprocate similar findings of morphological/morphometric prognostic studies in CRC reported by Mesker et al., 50, 51 Huijbers et al., 47 and West et al. 52 Collectively, our data and that of others 47,50-52 add substance to the concept that simple morphometric appraisal of the quantitative relationship between tumour and tumour-associated stroma can reliably identify patient subpopulations with different risks of tumour recurrence in a simple and cost-effective manner. Our group (led by A.W. and D.T.) is now in the process of using the described dataset to develop an automated computational analytical platform for CRC prognostication. 
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